G protein-coupled receptor 30 expression is up-regulated by EGF and TGFα in estrogen receptor α-positive cancer cells

Molecular Endocrinology

Volumn 23, Issue 11, 2009, Pages 1815-1826

  Vivacqua, Adele ^a   Lappano, Rosamaria ^a   De Marco, Paola ^a   Sisci, Diego ^a   Aquila, Saveria ^a   De Amicis, Francesca ^a   Fuqua, Suzanne A W ^b   Andò, Sebastiano ^a   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; ESTROGEN ACTIVITY; GENE SILENCING; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE; UP-REGULATION;

EID: 70350449695     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0120     Document Type: Article

References (76)

1. Pike MC, Pearce CL, Wu AH 2004 Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379-6391 (Pubitemid 39265506)
2. Hacker NF 2005 Uterine cancer. In: Berek JS, Hacker NF, eds. Practical gynecologic oncology. Philadephia: Lippincott Williams & Wilkins; 397-442
3. Tsai SY, Tsai MJ, O'Malley BW 1989 Cooperative binding of steroid hormone receptors contributes to transcriptional synergism at target enhancer elements. Cell 57:443-448
4. Kumar V, Chambon P 1988 The estrogen receptor binds to its responsive element as a ligand-induced homodimer. Cell 55:145-156 (Pubitemid 18243642)
5. Kampa M, Pelekanou V, Castanas E 2008 Membrane-initiated steroid action in breast and prostate cancer. Steroids 73:953-960
6. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Andò S 2004 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279:27008-27016 (Pubitemid 38812536)
7. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER 2005 A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630
8. Thomas P, Pang Y, Filardo EJ, Dong J 2005 Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146:624-632 (Pubitemid 40129818)
9. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, Maggiolini M 2006 The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631-646 (Pubitemid 43291214)
10. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S, Maggiolini M 2006 17β-Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupled-receptor GPR30. Mol Pharmacol 70:1414-1423 (Pubitemid 44435994)
11. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, AndòS, Maggiolini M 2007 G-protein couplet receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67:1859-1866 (Pubitemid 46383413)
12. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Pandey DP, Picard D, Mauro L, Andò S and Maggiolini M 2008 Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149:3799-3808
13. Dupont WD, Page DL 1991 Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67-72
14. Scott JA, McGuire WL 1991 New molecular markers of prognosis in breast cancer. New York: Raven Press; 179-196
15. Ponzone R, Biglia N, Jacomuzzi ME, Mariani L, Dominguez A, Sismondi P 2006 Antihormones in prevention and treatment of breast cancer. Ann NY Acad Sci 1089:143-158 (Pubitemid 47092092)
16. Jordan VC, Fritz NF, Tormey DC 1987 Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47:624-630 (Pubitemid 17009636)
17. Howell A, DeFriend D, Robertson J, Blamey R, Walton P 1995 Response to a specific antioestrogen (ICI 182780) in tamoxifenresistant breast cancer. Lancet 345:29-30
18. Early Breast Cancer Trialist' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-years survival: an overview of the randomized trials. Lancet 365:1687-1717 (Pubitemid 40719106)
19. Herynk MH, Fuqua SA 2007 Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol 608:130-143
20. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM 2002 Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-positive breast cancer. Ann NY Acad Sci 963:104-115 (Pubitemid 34721702)
21. Razandi M, Pedram A, Park ST, Levin ER 2003 Proximal events in signalling by plasma membrane estrogen receptors. J Biol Chem 278:2701-2712 (Pubitemid 36801351)
22. Song RX, Zhang Z, Santen RJ 2005 Estrogen rapid action via protein complex formation involving ERα and Src. Trends Endocrinol Metab 16:347-353 (Pubitemid 41338739)
23. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97:306-312
24. Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR 2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30 and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649-1660
25. Filardo EJ, Quinn JA, Frackelton Jr AR, Bland KI 2002 Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16:70-84
26. Hsieh M, Conti M 2005 G-protein-coupled receptor signalling and the EGF network in endocrine system. Trends Endocrinol Metab 16:320-326 (Pubitemid 41206639)
27. Booth BW, Smith GH 2007 Roles of transforming growth factor-α in mammary development and disease. Growth Factors 25:227-235
28. Madtes DK, Raines EW, Sakariassen KS, Assoian RK, Sporn MB, Bell GI, Ross R 1988 Induction of transforming growth factor α in activated human alveolar macrophages. Cell 53:285-293 (Pubitemid 18139065)
29. Wong DT, Weller PF, Galli SJ, Elovic A, Rand TH, Gallagher GT, Chiang T, Chou MY, Matossian K, McBride J, Todd R 1990 Human eosinophils express transforming growth factor α. J Exp Med 172:673-681 (Pubitemid 20301213)
30. Kumar V, Bustin SA, McKay IA 1995 Transforming growth factor α. Cell Biol Int 19:373-388
31. Swendeman S, Mendelson K, Weskamp G 2008 VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signalling. Circ Res 24:916-918
32. Lewis TS, Shapiro PS, Ahn NG 1998 Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139 (Pubitemid 28193546)
33. Schaeffer HJ, Weber MJ 1999 Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444
34. Guo L, Kozlosky CJ, Ericsson LH, Daniel TO, Cerretti DP, Johnson RS 2003 Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor. J Am Soc Mass Spectrom 14: 1022-1031 (Pubitemid 37040763)
35. Zwick E, Hackel PO, Prenzel N, Ullrich A 1999 The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 20:408-412 (Pubitemid 29450362)
36. Iordanov MS, Choi RJ, Ryabinina OP, Dinh TH, Bright RK, Magun BE 2002 The UV (ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-extracellular signal- regulated kinase signaling cascade from the activated epidermal growth factor receptor. Mol Cell Biol 22:5380-5394
37. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y 1999 Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4:1029-1040 (Pubitemid 30054908)
38. Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, Pierce JH, Lipkowitz S 1999 cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 18:1855-1866 (Pubitemid 29145853)
39. Pennock S, Wang Z 2008 A Tale of Two Cbls: Interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Mol Cell Biol 28:3020-3037 (Pubitemid 351556533)
40. Curran T, Franza Jr BR 1988 Fos and Jun: the AP1 connection. Cell 55:395-397
41. Filardo EJ, Quinn JA, Sabo E 2008 Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 73: 870-873
42. Stern DF 2000 Tyrosine kinase signaling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2:176-183 (Pubitemid 32223582)
43. Ebert AD, Wechselberger C, Martinez-Lacaci I, Bianco C, Weitzel HK, Salomon DS 2000 Expression and function of EGF-related peptides and their receptors in gynecological cancer-from basic science to therapy. J Recept Signal Transduct Res 20:1-46 (Pubitemid 30123163)
44. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL 2007 Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909-4919 (Pubitemid 47294799)
45. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI 2005 Epidermal growth factor receptor/HER2/insulin- like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Suppl 1):S99-S111 (Pubitemid 41395417)
46. Cunha GR, Wiesen JF, Werb Z, Young P, Hom YK, Cooke PS, Lubahn DB 2000 Paracrine mechanisms of mouse mammary ductal growth. Adv Exp Med Biol 480:93-97 (Pubitemid 32176098)
47. DiAugustine RP, Petrusz P, Bell GI, Brown CF, Korach KS, McLachlan JA, Teng CT 1988 Influence of estrogens on mouse uterine epidermal growth factor precursor protein and messenger ribonucleic acid. Endocrinology 122:2355-2363 (Pubitemid 18152222)
48. Mukku VR, Stancel GM 1985 Regulation of epidermal growth factor receptor by estrogen. J Biol Chem 260:9820-9824 (Pubitemid 15013041)
49. Nelson KG, Takahashi T, Bossert NL, Walmer DK, McLachlan JA 1991 Epidermal growth factor replaces estrogen in the stimulation of female genital tract growth and differentiation. Proc Natl Acad Sci USA 88:21-25 (Pubitemid 21914417)
50. Filardo EJ 2002 Epidermal Growth Factor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signalling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80:231-238
51. Filardo EJ, Thomas P 2005 GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16:362-367 (Pubitemid 41338741)
52. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, Maggiolini M 2008 G-protein-coupled receptor 30 and estrogen receptor-α are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ Health Perspect 116:1648-1655
53. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M 2006 Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818-826
54. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM 2004 HER-2 amplification, HER-1 expression, and tamoxifen rensponse in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. Clin Cancer Res 10: 5670-5676
55. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM 2005 Estrogen receptor-positive, progesterone receptor- negative breast cancer. Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261 (Pubitemid 41535366)
56. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C 2006 A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 12:1175-1183 (Pubitemid 43342506)
57. Osborne CK, Shou J, Massarweh S, Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-870s (Pubitemid 40111098)
58. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L 2000 HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471-3479 (Pubitemid 30783325)
59. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935 (Pubitemid 38868139)
60. Pérez-Tenorio G, Stål O 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545 (Pubitemid 34185089)
61. Gee JM, Robertson JF, Ellis IO, Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247-254
62. Nicholson S, Halcrow P, Sainsbury JR, Angus B, Chambers P, Farndon JR, Harris AL 1988 Epidermal growth factor receptor (EGFR) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58: 810-814 (Pubitemid 19033402)
63. Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL 2007 Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 25:3007-3014 (Pubitemid 47218046)
64. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833 (Pubitemid 351206760)
65. Giordano C, Cui Y, Barone I, AndòS, Mancini MA, Berno V, Fuqua SA 2009 Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305. Breast Cancer Res Treat 10.1007/s10549-009-0334-340
66. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S 2005 A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748 (Pubitemid 41557193)
67. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361 (Pubitemid 36395255)
68. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK 1992 Estrogen-dependent, tamoxifen- resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95 (Pubitemid 23063891)
69. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I 2003 The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80 (Suppl 1):S29 -S34; discussion, S35 (Pubitemid 37108449)
70. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81:81-93 (Pubitemid 37108443)
71. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887-5894 (Pubitemid 30808328)
72. Prakash Pandey D, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D 2009 Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28:523-532
73. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER 2007 GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196:386.e1-9; discussion 386.e9-e11 (Pubitemid 46497934)
74. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E 2006 Distribution of GPR30, a seven membrane spanning estrogen receptor, in primary breast cancer and its association with clinico pathologic determinants of tumor progression. Clin Cancer Res 12:6359-6366 (Pubitemid 44799705)
75. Herman ME, Katzenellenbogen BS 1996 Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 59:121-134
76. Morelli C, Garofalo C, Sisci D, del Rincon S, Cascio S, Tu X, Vecchione A, Sauter ER, Miller Jr WH, Surmacz E 2004 Nuclear insulin receptor substrate 1 interacts with estrogen receptor α at ERE promoters. Oncogene 23:7517-7526 (Pubitemid 39389693)